CompletedNot Applicable

MEOI and HRQoL in CLL Patients Treated With BTKis

United States23 participantsStarted 2021-10-07

Plain-language summary

This is a multi-site observational study of medical events of interest (MEOI) and health-related quality of life (HRQoL) in chronic lymphocytic leukemia (CLL) patients initiating treatment with the Bruton's tyrosine kinase inhibitors (BTKi) acalabrutinib or ibrutinib in the United States (US)

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ≥18 years old * Physician-confirmed diagnosis of CLL or small lymphocytic lymphoma (SLL) * BTKi naïve patients who initiate acalabrutinib or ibrutinib treatment alone or in combination with an anti-CD20 mAb within 7 days (before or after) study enrollment\*. Both treatment naïve and relapsed/refractory CLL patients will be included. * Provides informed consent * Adequate English reading skills * Able to access and use a computer, tablet, or smartphone to complete PROs Exclusion Criteria: * Use of BTKi any time prior to study enrollment. * Currently receiving systemic treatment for another malignancy * Currently enrolled in a clinical trial

What they're measuring

Patient Characteristics

Timeframe: Baseline

Chart Recorded Medical Events of Interest

Timeframe: 24 Month Follow-up

Patient Reported Medical Events of Interest

Timeframe: 24 month follow-up

HRQoL

Timeframe: 24 month follow-up

Trial details

NCT IDNCT04938141

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-09-26

View on ClinicalTrials.gov More Chronic Lymphocytic Leukemia trials